Spark Therapeutics (NASDAQ:ONCE) was the recipient of unusually large options trading activity on Thursday. Investors acquired 551 put options on the stock. This is an increase of 884% compared to the average volume of 56 put options.
Several equities research analysts recently weighed in on the stock. ValuEngine raised shares of Spark Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 9th. BMO Capital Markets set a $64.00 target price on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 21st. Mizuho set a $79.00 target price on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Thursday, March 29th. Raymond James Financial set a $66.00 target price on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 21st. Finally, Sanford C. Bernstein reaffirmed a “buy” rating and set a $60.00 target price (down from $71.00) on shares of Spark Therapeutics in a research note on Wednesday, February 21st. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, five have issued a hold rating and seventeen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $70.58.
NASDAQ ONCE opened at $77.04 on Friday. Spark Therapeutics has a 52 week low of $41.06 and a 52 week high of $91.75. The company has a market cap of $2,826.30, a price-to-earnings ratio of -10.10 and a beta of 2.56.
Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings results on Tuesday, February 20th. The biotechnology company reported ($1.73) EPS for the quarter, hitting the consensus estimate of ($1.73). Spark Therapeutics had a negative net margin of 2,100.80% and a negative return on equity of 59.38%. The company had revenue of $7.41 million during the quarter, compared to analysts’ expectations of $9.53 million. equities analysts forecast that Spark Therapeutics will post -3.33 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its holdings in Spark Therapeutics by 1.4% during the 4th quarter. BlackRock Inc. now owns 2,650,258 shares of the biotechnology company’s stock worth $136,277,000 after acquiring an additional 35,801 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Spark Therapeutics by 46.4% in the 3rd quarter. Janus Henderson Group PLC now owns 756,088 shares of the biotechnology company’s stock valued at $67,413,000 after buying an additional 239,723 shares in the last quarter. Clearbridge Investments LLC boosted its holdings in shares of Spark Therapeutics by 2.9% in the 4th quarter. Clearbridge Investments LLC now owns 687,444 shares of the biotechnology company’s stock valued at $35,348,000 after buying an additional 19,492 shares in the last quarter. Rock Springs Capital Management LP boosted its holdings in shares of Spark Therapeutics by 3.0% in the 4th quarter. Rock Springs Capital Management LP now owns 615,000 shares of the biotechnology company’s stock valued at $31,623,000 after buying an additional 18,000 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC acquired a new position in shares of Spark Therapeutics in the 4th quarter valued at $28,188,000.
COPYRIGHT VIOLATION WARNING: “Traders Buy Large Volume of Put Options on Spark Therapeutics (ONCE)” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/14/traders-buy-large-volume-of-put-options-on-spark-therapeutics-once.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.